P
Pramit M. Phal
Researcher at University of Melbourne
Publications - 53
Citations - 1735
Pramit M. Phal is an academic researcher from University of Melbourne. The author has contributed to research in topics: Bevacizumab & Randomized controlled trial. The author has an hindex of 17, co-authored 53 publications receiving 1473 citations. Previous affiliations of Pramit M. Phal include Royal Melbourne Hospital & University of New South Wales.
Papers
More filters
Journal ArticleDOI
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Matthew K.H. Hong,Geoff Macintyre,David C. Wedge,Peter Van Loo,Keval M. Patel,Sebastian Lunke,Ludmil B. Alexandrov,Clare Sloggett,Marek Cmero,Francesco Marass,Dana W.Y. Tsui,Stefano Mangiola,Andrew Lonie,Haroon Naeem,Nikhil Sapre,Pramit M. Phal,Natalie Kurganovs,Xiaowen Chin,Michael Kerger,Anne Y. Warren,David E. Neal,Vincent Gnanapragasam,Nitzan Rosenfeld,John Pedersen,Andrew Ryan,Izhak Haviv,Anthony J. Costello,Niall M. Corcoran,Christopher M. Hovens +28 more
TL;DR: The precise direction of metastatic spread is revealed across four lethal prostate cancer patients using whole-genome and ultra-deep targeted sequencing of longitudinally collected primary and metastatic tumours and analysis of mutations associated with metastasis reveals an enrichment of TP53 mutations.
Journal ArticleDOI
Qualitative Comparison of 3-T and 1.5-T MRI in the Evaluation of Epilepsy
Pramit M. Phal,Alexander Usmanov,Gary M. Nesbit,James C. Anderson,David Spencer,Paul Wang,Jonathan A. Helwig,Colin M. Roberts,Bronwyn E. Hamilton +8 more
TL;DR: MRI at 3 T performed better than 1.5-T MRI in image quality, detection of structural lesions, and characterization of lesions in evaluation of epilepsy, and high-field-strength imaging should be considered for patients with intractable epilepsy.
Journal ArticleDOI
Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws
TL;DR: The most common finding in bisphosphonate-associated osteonecrosis was osseous sclerosis, which varied from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis-like sclerosis.
Journal ArticleDOI
Incidence of cerebral microbleeds in preclinical Alzheimer disease
Paul Yates,Patricia Desmond,Patricia Desmond,Pramit M. Phal,Christopher Steward,Christopher Steward,Cassandra Szoeke,Cassandra Szoeke,Olivier Salvado,Kathryn A. Ellis,Ralph N. Martins,Colin L. Masters,David Ames,Victor L. Villemagne,Christopher C. Rowe +14 more
TL;DR: Older age, baseline LMBs, higher β-amyloid burden, and concomitant cerebrovascular disease may all confer higher risk of incident L MBs, and should be considered when designing protocols for amyloid-modifying clinical trials.
Journal ArticleDOI
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field,John Simes,Anna K. Nowak,Lawrence Cher,Helen Wheeler,Elizabeth Hovey,Chris Brown,Elizabeth H Barnes,Kate Sawkins,Ann Livingstone,Ron Freilich,Pramit M. Phal,Gregory J Fitt,Cabaret,Cogno investigators,Mark Rosenthal +15 more
TL;DR: Adding carboplatin resulted in more toxicity without additional clinical benefit, and clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies.